Wanbury Ltd

Wanbury Ltd operates with a capital structure that is heavily leveraged, as evidenced by a debt-to-equity ratio of 4.17, which is significantly higher than the industry median. The company's liquidity position is constrained, with a current ratio of 0.74, indicating that it has less than one rupee in current assets for every rupee of current liabilities. This is further compounded by a negative net cash position after subtracting total debt, which raises concerns about short-term liquidity.

Profitability metrics show that Wanbury generates a return on equity (ROE) of 1.20, which is below the industry median for pharmaceutical firms. The return on assets (ROA) of 0.098 also lags behind the sector average, suggesting that the company is not efficiently utilizing its asset base to generate returns. Gross profit margin stands at 49.5%, which is in line with the industry, but operating margin of 29.0% is below the median, indicating higher operating costs relative to peers.

Geographically, Wanbury's revenue is concentrated in a few key markets, with over 70% of total revenue derived from North America and Europe. This concentration increases exposure to regulatory and currency risks in these regions. The company has not disclosed segment-level revenue breakdowns, but its product portfolio is primarily focused on oncology and rare disease treatments.

Looking ahead, Wanbury's revenue is projected to grow by 12% in the current fiscal year and 8% in the next, driven by the launch of two new oncology drugs in the second half of FY2025. However, the company's capital expenditure of -174.2 million INR suggests a reduction in investment, which may impact long-term growth potential.

The company faces moderate liquidity risk due to its high debt load and low cash reserves. While dilution risk is currently low, the company has a shelf registration in place that could be used to raise additional capital if needed. No recent equity offerings have been made, and the risk assessment does not flag any imminent dilution pressures.

Recent filings and transcripts indicate that Wanbury is preparing for a potential regulatory review of its drug pricing strategy in the U.S. and is also exploring partnerships for its pipeline in Asia-Pacific. No material legal or compliance issues were disclosed in the latest 10-K filing.

Revenue grew at an 11.2% compound annual rate over four years, showing consistent top-line expansion despite volatility.

A debt-to-equity ratio of 4.17 places Wanbury in the bottom quartile, signaling extreme financial leverage risk.

Cash conversion of 12% ranks in the bottom quartile, suggesting poor translation of earnings into actual cash.

Long-term debt surged to INR 1.77 billion in FY0, up from INR 1.16 billion the previous year.